Evidence map›Paper›PMID 33718859›Full record

ArticleMatrix biology plus2021

A glycine substitution in the collagenous domain of Col4a3 in mice recapitulates late onset Alport syndrome.

Christoforos Odiatis, Isavella Savva, Myrtani Pieri, Pavlos Ioannou, Petros Petrou, Gregory Papagregoriou, Kyriaki Antoniadou, Neoklis Makrides, Charalambos Stefanou, Danica Galešić Ljubanović and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Matrix biology plus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Genotype-Based Molecular Mechanisms in Alport Syndrome.Journal of the American Society of Nephrology : JASN · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 5 countries.

Christoforos OdiatisCenter of Excellence in Biobanking and Biomedical Research, Molecular Medicine Research Center, University of Cyprus Medical School, Cyprus.
Isavella SavvaCenter of Excellence in Biobanking and Biomedical Research, Molecular Medicine Research Center, University of Cyprus Medical School, Cyprus.
Myrtani PieriDepartment of Life and Health Sciences, School of Sciences and Engineering, University of Nicosia, Cyprus.
Pavlos IoannouCenter of Excellence in Biobanking and Biomedical Research, Molecular Medicine Research Center, University of Cyprus Medical School, Cyprus.
Petros PetrouDepartment of Biochemistry, The Cyprus Institute of Neurology and Genetics, Cyprus.
Gregory PapagregoriouCenter of Excellence in Biobanking and Biomedical Research, Molecular Medicine Research Center, University of Cyprus Medical School, Cyprus.
Kyriaki AntoniadouCenter of Excellence in Biobanking and Biomedical Research, Molecular Medicine Research Center, University of Cyprus Medical School, Cyprus.
Neoklis MakridesDepartment of Developmental Functional Genetics, The Cyprus Institute of Neurology and Genetics, Cyprus.
Charalambos StefanouCenter of Excellence in Biobanking and Biomedical Research, Molecular Medicine Research Center, University of Cyprus Medical School, Cyprus.
Danica Galešić LjubanovićDepartment for Nephropathology and Electron microscopy, University of Zagreb, Croatia.
Georgios NikolaouVeterinary diagnostic laboratory, Vet ex Machina LTD, Nicosia, Cyprus.
Dorin-Bogdan BorzaDept. of Microbiology, Immunology and Physiology, Meharry Medical College, Nashville, TN, United States of America.
Kostas StylianouDepartment of Nephrology, University of Crete Medical School, Greece.
Oliver GrossClinic for Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany.
Constantinos DeltasCenter of Excellence in Biobanking and Biomedical Research, Molecular Medicine Research Center, University of Cyprus Medical School, Cyprus.
University of Cyprus · CYCyprus Institute of Neurology and Genetics · CYMeharry Medical College · USUniversitätsmedizin Göttingen · DEUniversity of Crete · GRUniversity of Nicosia · CYUniversity of Zagreb · HR

Funding

Technologies and Resources CoreU54MD007593 · NIMHD · MEHARRY MEDICAL COLLEGE · PI ADUNYAH, SAMUEL EVANS · 2012 to 2018
$24.7M
NIMHD NIH HHS U54 MD007593
6 · The paper itself

Abstract

Alport syndrome (AS) is a severe inherited glomerulopathy caused by mutations in the genes encoding the α-chains of type-IV collagen, the most abundant component of the extracellular glomerular basement membrane (GBM). Currently most AS mouse models are knockout models for one of the collagen-IV genes. In contrast, about half of AS patients have missense mutations, with single aminoacid substitutions of glycine being the most common. The only mouse model for AS with a homozygous knockin missense mutation, Col4a3-p.Gly1332Glu, was partly described before by our group. Here, a detailed in-depth description of the same mouse is presented, along with another compound heterozygous mouse that carries the glycine substitution

Indexed as

Alport syndromeARAS, autosomal recessive alport syndromeAS, alport syndromeBSA, bovine serum albuminCollagen-IVEM, electron microscopyESRD, end stage renal diseaseGBM, glomerular basement membraneGlomerular basement membraneGlycine missense mutationKidney diseaseMouse modelPAS, periodic acid schiffTBM, tubular basement membraneTGF-b1, transforming growth factor beta1UPR, unfolded protein response

Identifiers

PMID33718859
PMCPMC7930875
OpenAlexW3117836548

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.